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Cyanogen bromide and tryptic fragments of penicilloylated serum albumin from penicillin-treated patients were separated 
by HPLC. Determinations of benzylpenicilloyl (BPO) were performed on the different fractions. A BP0 containing 
peptide was identified by its ammo acid sequence and the bound BP0 group was located on the lysine residue 199. 
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1. INTRODUCTION 
Benzylpenicilloyl groups (BPO) result from the 
cleavage of the ,8 lactam ring of penicillin G. They 
form covalent binding between their carbonyl 
group and c-amino groups of albumin molecules. 
They thus give rise to penicilloyl-albumin con- 
jugates which have lost all antibacterial activity but 
possess lir.1 I,llllllllr~W>?ti “flJ~W&$ BP0 Th’;t &&S ” ;mmrrn 
considered to be the major antigenic determinant 
in penicillin allergy [l-3]. 
In patients treated with large amounts of 
peni&& a %a&e& %is&&~i~~~i~ ‘w’hs &- 
served [4], and it has been demonstrated that the 
covalent fixation of BP0 was responsible for the 
presence af <ke fasC. &~<r~tiW+z &a& of 
albumin [5]. Recently BP0 binding sites were 
located on cyanogen bromide (CNBr) fragments of 
serurm gIaurrirnErom_uerit~Ilitn~rre~te&_u~~~e~t~.~ne 
fixation occurring mainly on fragment C124-298 
and on the C-terminal fragment A299-585 [6]. 
The purpose of this work was to identify the 
sites of BP0 fixation on fragment C of fast serum 
albumin malecules. 
2. MATERIALS AND METHODS 
2.1. Reagents and serum 
For high-performance liquid chromatography (HPLC), all 
the chemicals used were of HPLC grade, the water was filtered 
through an Elgastat UHQ system and the solvents were de- 
gassed before use. 
For amino acid analysis, as for recurring Edman degrada- 
tion, the chemicals used were of sequanol grade. The other 
reagents were of analytical grade. 
Serum was btimti kom a pakm in ‘rhe ‘m3+rnm ?aS%eur 
Hospital, who received intravenously 50 x lo6 IU penicillin G 
per day for 22 days. The collect was achieved 2 days after cessa- 
tion of the treatment. The fast serum albumin was separated as 
described by Lapresle and Wal [5]. 
2.2. CNBr digestion of fast albumin and HPLC separation of 
fragmenb 
CNBr cleavage was carried out on IO mg of fast albumin as 
described [7]. Separation of fragments was performed by 
reversed phase HPLC using a Waters Ass. chromatographic 
system. The CNBr digest was dissolved in 1 ml of solvent A 
I.?J.%% aqueous x%&ion -61 ‘rifinmxix&irc a&‘~WQl. %I &i 
were injected onto an Aquapore RP-300 column (7 Frn, 30 x 
4.6 mm i.d.) (Brownlee), equilibrated in a mixture of 50% sol- 
vent A and 50% solvent B (acetonitrile/2-propanol/water 
(2: 1: 2, v/v), 0.05% TFA). 
Elution of peptides was achieved with a 30 min linear gra- 
bjent from 50 $0 Im% of sokent Bat z flow rak of 1 mlkin. 
All runs were performed at room temperature and peptides 
were detected at 215 nm. Fractions were collected every 30 s us- 
ing a TDC 80 microcol (Gilson). 20 runs were performed, the 
f<Z&kr~ Q?X?Z ~‘ks! &Z&Z! t&X &Xc& Qizs Mm??& &z&g d 
Speed Vat evaporator. 
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2.3. Tryptic digestion of fragment C, carboxymethylation a d 
separation of peptides 
Fragment C124-298 obtained from the CNBr digest was 
dissolved in 0.1 M phosphate buffer, pH 7.8, and digested over- 
night with TPCK-trypsin (Sigma) (enzyme/substrate, 1: 20) at 
room temperature. 
Reduction and carboxymethylation were performed directly 
on the tryptic digest, as described [8]. The mixture was then 
fractionated on a Nucleosil 5-Cl8 column (5 pm, 25 cm x 
4.6 mm i.d.) (Societe Francaise Chromato Colonne) 
equilibrated with solvent A. A linear gradient was operated, 
over 30 min, at 1 ml/min from 0 to 100% solvent B. Fractions, 
collected every 30 s, were evaporated to dryness. 
The BP0 containing fractions were then purified on the same 
column, using the same linear gradient at the same flow rate but 
with another elution system: solvent A’ : 0.01 M phosphate buf- 
fer, pH 7, and solvent B’: solvent A’/acetonitrile (40:60, v/v). 
Fractions were collected every 0.1 min. 
2.4. Detection of the penicilloyl groups 
All the dried fractions collected from the analysis of CNBr 
and tryptic digests were dissolved in 0.1 ml water and the BP0 
detection was performed using an enzymoimmunoassay directly 
derived from the radioimmunoassay as described [9]. 
2.5. Identification of peptides 
Amino acid analyses were performed with a Biotronik LC 
5000 Analyzer after acid hydrolysis (5.7 N HCl, in vacua, 
llO”C, 24 h). The C-terminal amino acids were identified by 
amino acid analysis after reaction with carboxypeptidase A 
(Boehringer); the N-terminal amino acids were identified by the 
recurring Edman degradation using Tarr’s procedure [lo]. 
Sequencing was achieved using a 470A sequenator connected 
to a 120A PTH HPLC analyzer (Applied Biosystems). 
3. RESULTS 
3.1. Obtainment and identification of the 
penicilloylated fragment C after CNBr 
cleavage of the fast albumin 
Under the HPLC conditions described for the 
CNBr digest, two penicilloyl containing peaks were 
observed. 
The first peptide, eluted at a retention time (RT) 
of 8.9 min was identified to the fragment Cr24_298 
by its amino acid analysis and by the determination 
of the C-terminal and N-terminal amino acids. 
3.2. Obtainment of the penicilloylated peptides 
after tryptic digestion of fragment C 
Fig. 1 shows the chromatographic pattern of the 
tryptic digest, using the trifluoroacetic acid elution 
system (solvents A and B). Two BP0 containing 
peaks are collected, e.g. RT 17 and 21 min. The 
HPLC of these two peaks using the second elution 
system (solvents A’ and B’) demonstrated that 
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Fig. 1. HPLC separation (TFA/acetonitrile/propanol) of the 
tryptic fragments from the fragment C124-29s of the 
penicilloylated HSA. (-) Peptide determination at 215 nm; 
(---) EIA determination of BP0 on the corresponding 
fractions. 
peak 17 actually was a mixture of two 
penicilloylated fragments while peak 21 appeared 
to contain only a single BPO-peptide separated 
and collected at a RT of 16.8 min. Fig.2 shows the 
HPLC separation of this ‘peptide 16’. 
3.3. Identification of peptide 16 
The amino acid sequencing of this peptide gave 
the following pattern: 
Leu- -CM Cys-Ala-Ser-Leu-Gln-Lys 
_--_____ 
No amino acid could have been identified at the 
second step of the sequencing. The sequence of the 
peptide 198-205 of the ‘normal’ serum albumin 
(e.g. Leu-Lys-Cys-Ala-Ser-Leu-Gln-Lys) sug- 
gests that binding of the BP0 group occurs on 
Lys-199. 
The BP0 determinations were done again on 
each of the four first steps of the recurring Edman 
degradation of peptide 16. Most of the BP0 was 
detected on the second step (corresponding to 
Lys-199). Only traces corresponding to a =lO% 
overlap were detected on the third step while no 
BP0 could have been detected on the first and 
fourth step, nor on the residual tetrapeptide. No 
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Fig.2. HPLC purification (phosphate buffer/acetonitrile) of the peak 21. (-) Peptide determination at 215 nm; (---) El.4 
determination of BP0 on the corresponding fractions. 
false positive result was observed in the EIA of a 
blank phenylthiohydantoin lysine derivative. 
4. DISCUSSION 
This work confirms our first observations on 
bisalbuminemia induced by penicillin therapy 
showing the presence of covalently bound BP0 on 
the fast albumin molecules [5]. It also confirms the 
recent result from Lafaye and Lapresle [6] 
demonstrating that one major site of BP0 fixation 
was fragment C124_298, as well as the previous 
classical assumption that e-amino groups of lysine 
were implicated in the formation of the allergenic 
metabolite of penicillin, e.g. BPO-protein con- 
jugates [ 1,2]. 
The identification of Lys-199 of HSA as a bin- 
ding site for BP0 is to be compared to results ob- 
tained with other ligands. Walker [l l] demon- 
strated that, under physiological conditions, lysine 
residue 199 reacts specifically with acetylsalicylic 
acid which thus transfers its acetyl group to HSA. 
Lysine 199 appears to be also a major site of the 
non-enzymatic glycosylation in vitro, this 
glycosylation being inhibited by aspirin [12]. In 
vivo, glucose becomes attached to Lys-199 too 
although it is not then the principal site of 
glycosylation [ 13,141. The discrepancy between the 
rates of glycosylation of Lys-199 observed in vivo 
and in vitro could possibly result from the fact that 
in vivo the f-amino group of Lys-199 is already 
covered by a ligand which would affect the 
availability of this site for glucose as suggested by 
Garlick et al. [13]. It could be hypothesized that in 
some cases, drugs such as BP0 could be such a 
ligand. 
Lys-199 has also been identified as one of the 
rapidly reacting lysines of HSA with 2,6-dinitro-4- 
trifluoromethyl benzene sulfonate [ 151. 
In all these studies authors emphasize the role of 
the low pKa of the e-amino group of Lys-199, e.g. 
7.9 according to Iberg and Fluckiger [ 141, whereas 
the other lysine e-amino groups are likely to have 
pK values near 11. The lower pK should facilitate 
reaction with ligands since the reactive amino 
group must be uncharged for the chemical 
modification to occur. Similar observations were 
made concerning the in vitro aminolysis of 
penicillin in the presence of various amines, the 
reaction being more rapid and extensive as the pK 
of the amine acceptor was close to the pH of the 
reaction [16-181. 
Lysine residue 199 thus appears to be an impor- 
tant binding site, for several ligands, in albumin 
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molecules. Concerning BP0 fixation, it is largely 
implicated even if it is not the only site, as can be 
assumed from the HPLC patterns obtained as well 
as from previous observations on the elec- 
trophoretic heterogeneity of fast albumin [5] and 
from the results of Lafaye and Lapresle [6]. 
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